TVTX financials
Travere Therapeutics (TVTX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
TVTX income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $490.73M | $480.39M | -$62.82M | -$25.55M | -0.56 |
| 2024 | $233.18M | $225.43M | -$323.83M | -$321.55M | -4.08 |
| 2023 | $145.24M | $133.79M | -$388.14M | -$111.40M | -1.50 |
| 2022 | $109.46M | $105.04M | -$319.81M | -$278.48M | -4.37 |
| 2021 | $131.84M | $128.02M | -$199.43M | -$180.09M | -3.01 |
| 2020 | $198.32M | $192.19M | -$176.16M | -$169.43M | -3.56 |
- TVTX revenue was $490.73M in fiscal 2025, net income -$25.55M.
Updated 2026-11-07 11:56 UTC